Deepak Kilari, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Telugu, Hindi

New & Established Patients Call

(414) 777-7700

Education

MD - Doctor of Medicine

Biography

Deepak Kilari, MD, is an assistant professor in the division of hematology and oncology at the Medical College of Wisconsin. Dr. Kilari moved back to the United States after finishing medical school at Andhra Medical College, India, to finish his internal medicine training at New York Methodist Hospital. In the course of his residency, he developed an interest in Oncology during his rotations at the Memorial Sloan Kettering Cancer Center, New York. Subsequently, he completed a fellowship in hematology and oncology at the University of Rochester, where he also served as a chief fellow. He received the American Society of Clinical Oncology (ASCO) Foundation Merit award in 2013. Dr. Kilari practices at Froedtert & the Medical College of Wisconsin Clinical Cancer Center and Moorland Reserve Clinic where he specializes in the management of patients with Genitourinary malignancies.

Research Interests

Dr. Kilari's clinical research interests focus on the development of better treatment options for patients with genitourinary malignancies. Dr. Kilari is Board Certified in Medical Oncology and Hematology.

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.

(Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ.) JCO Precis Oncol. 2024 Apr;8:e2300567 PMID: 38579192 04/05/2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).

(Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group.) J Clin Oncol. 2024 Apr 01;42(10):1114-1123 PMID: 38261983 01/23/2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.

(Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T.) Prostate Cancer Prostatic Dis. 2024 Feb 22 PMID: 38383885 02/22/2024
Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis.

(Hakimi K, Saidian A, Panian J, Barata P, Berg S, Chang SL, Saliby RM, Dzimitrowicz H, Emamekhoo H, Gross E, Kilari D, Lam E, Nguyen M, Meagher M, Wang L, Rauterkus GP, D'Andrea V, Yim K, Psutka S, Thapa B, Weise N, Zhang T, McKay RR, Derweesh IH.) Clin Genitourin Cancer. 2023 Dec;21(6):694-702 PMID: 37558529 SCOPUS ID: 2-s2.0-85167777292 08/10/2023
5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy.

(Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) medRxiv. 2023 Oct 16 PMID: 37904926 PMCID: PMC10615016 10/31/2023
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.

(Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC.) JAMA Netw Open. 2023 Sep 05;6(9):e2334208 PMID: 37721753 PMCID: PMC10507489 SCOPUS ID: 2-s2.0-85171513698 09/18/2023
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.

(Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A.) Res Sq. 2023 Aug 10 PMID: 37609284 PMCID: PMC10441451 08/23/2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.

(Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR.) Oncologist. 2023 Jun 27 PMID: 37368355 06/27/2023
The Confusion Surrounding Androgen Deprivation Therapy and Cognitive Dysfunction.

(Pierro MJ, Kilari D.) Eur Urol Focus. 2023 May;9(3):409-410 PMID: 37005166 SCOPUS ID: 2-s2.0-85151400919 04/03/2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.

(Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y.) J Immunother Cancer. 2023 Feb;11(2) PMID: 36822667 PMCID: PMC9950974 SCOPUS ID: 2-s2.0-85148679955 02/24/2023
Comprehensive genomic profiling: Does timing matter?

(Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B.) Front Oncol. 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 03/04/2023